Pfizer Research Grant Request for Proposals: Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
Pfizer funds real-world research on elranatamab for relapsed/refractory multiple myeloma, emphasizing safety, effectiveness, and care delivery in diverse patient populations.
Funder: Pfizer Inc.
Due Dates: June 12, 2026: Full application submission deadline (applications must be submitted by 23:59 Eastern Standard Time, e.g., New York, GMT -5)
Funding Amounts: Up to $200,000 per project (smaller requests around $50,000 encouraged); maximum $250,000 with strong justification; up to 10 projects funded.
Summary: Supports independent real-world research on elranatamab in relapsed/refractory multiple myeloma, focusing on safety, effectiveness, and care delivery in diverse populations.
Key Information: Applications submitted after the deadline will not be reviewed; only organizations in China, France, Germany, Italy, Japan, Spain, Turkey, and the UK are eligible.
Description
This competitive grant program, offered by Pfizer Inc., aims to support independent real-world research evaluating the safety, effectiveness, and implementation of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM). The program emphasizes research on treatment sequencing, real-world utilization, and outcomes in diverse and underrepresented patient populations, including older adults and those with comorbidities. Projects should also address care delivery models that overcome educational, organizational, and system-level barriers, particularly in community practice settings. The ultimate goal is to generate evidence that informs clinical decision-making and improves patient outcomes in everyday care.
